EU/3/09/699

About

On 26 November 2009, orphan designation (EU/3/09/699) was granted by the European Commission to LFB-Biotechnologies, France, for recombinant chimeric monoclonal antibody against CD20 for the treatment of chronic lymphocytic leukaemia.

The sponsorship was transferred to Cambridge Regulatory Services Ltd, United Kingdom, in May 2018.

The sponsorship was transferred to CambPharma Solutions (CY) Limited, Cyprus, in July 2019. The sponsor’s address was updated in May 2020.

Key facts

Active substance
Recombinant chimeric monoclonal antibody against CD20 (ublituximab)
Disease / condition
Treatment of chronic lymphocytic leukaemia
Date of first decision
26/11/2009
Outcome
Positive
EU designation number
EU/3/09/699

Review of designation

This medicine is now known as ublituximab.

Sponsor's contact details

CambPharma Solutions (CY) Limited
Agiou Athanasiou 59
D. Vrachimis Building
Agios Athanasios
Limassol 4102
Cyrpus
Tel. +357 22 232288
E-mail: pallavshah@cambreg.co.uk

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

How useful was this page?

Add your rating